223 related articles for article (PubMed ID: 16896510)
21. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem.
Cramer JA; Silverman S
Am J Med; 2006 Apr; 119(4 Suppl 1):S12-7. PubMed ID: 16563936
[TBL] [Abstract][Full Text] [Related]
22. The impact of GI events on persistence and adherence to osteoporosis treatment: 3-, 6-, and 12-month findings in the MUSIC-OS study.
Modi A; Sen S; Adachi JD; Adami S; Cortet B; Cooper AL; Geusens P; Mellström D; Weaver JP; van den Bergh JP; Keown P; Sajjan S
Osteoporos Int; 2018 Feb; 29(2):329-337. PubMed ID: 29110061
[TBL] [Abstract][Full Text] [Related]
23. Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.
Wang Z; Ward MM; Chan L; Bhattacharyya T
Osteoporos Int; 2014 Aug; 25(8):2109-16. PubMed ID: 24846316
[TBL] [Abstract][Full Text] [Related]
24. Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
Palacios S; Agodoa I; Bonnick S; Van den Bergh JP; Ferreira I; Ho PR; Brown JP
J Clin Endocrinol Metab; 2015 Mar; 100(3):E487-92. PubMed ID: 25514106
[TBL] [Abstract][Full Text] [Related]
25. Adherence, patient preference and dosing frequency: understanding the relationship.
Reginster JY; Rabenda V; Neuprez A
Bone; 2006 Apr; 38(4 Suppl 1):S2-6. PubMed ID: 16520104
[TBL] [Abstract][Full Text] [Related]
26. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
Wang CC; Lu HT; Dusetzina SB; Wu CH
J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
[TBL] [Abstract][Full Text] [Related]
27. Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis.
Rhee CW; Lee J; Oh S; Choi NK; Park BJ
Osteoporos Int; 2012 Jan; 23(1):247-54. PubMed ID: 21431993
[TBL] [Abstract][Full Text] [Related]
28. The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases.
Brankin E; Walker M; Lynch N; Aspray T; Lis Y; Cowell W
Curr Med Res Opin; 2006 Jul; 22(7):1249-56. PubMed ID: 16834823
[TBL] [Abstract][Full Text] [Related]
29. Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.
Cole RE
Postgrad Med; 2011 Mar; 123(2):131-44. PubMed ID: 21474901
[TBL] [Abstract][Full Text] [Related]
30. Influence of patient training on persistence, compliance, and tolerability of different dosing frequency regimens of bisphosphonate therapy: An observational study in Turkish patients with postmenopausal osteoporosis.
Akarırmak Ü; Koçyiğit H; Eskiyurt N; Esmaeilzadeh S; Kuru Ö; Yalçinkaya EY; Peker Ö; Ekim AA; Özgirgin N; Çalış M; Rezvani A; Çevikol A; Eyigör S; Şendur ÖF; İrdesel J;
Acta Orthop Traumatol Turc; 2016 Aug; 50(4):415-23. PubMed ID: 27524671
[TBL] [Abstract][Full Text] [Related]
31. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan.
Soong YK; Tsai KS; Huang HY; Yang RS; Chen JF; Wu PC; Huang KE
Osteoporos Int; 2013 Feb; 24(2):511-21. PubMed ID: 22588182
[TBL] [Abstract][Full Text] [Related]
32. A systematic review of persistence and compliance with bisphosphonates for osteoporosis.
Cramer JA; Gold DT; Silverman SL; Lewiecki EM
Osteoporos Int; 2007 Aug; 18(8):1023-31. PubMed ID: 17308956
[TBL] [Abstract][Full Text] [Related]
33. Compliance with drug therapy for postmenopausal osteoporosis.
Weycker D; Macarios D; Edelsberg J; Oster G
Osteoporos Int; 2006; 17(11):1645-52. PubMed ID: 16862397
[TBL] [Abstract][Full Text] [Related]
34. Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.
Binkley N; Martens MG; Silverman SL; Derman RJ; Greenwald M; Kohles JD; Bachmann GA
South Med J; 2009 May; 102(5):486-92. PubMed ID: 19373149
[TBL] [Abstract][Full Text] [Related]
35. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis.
Cotté FE; Fardellone P; Mercier F; Gaudin AF; Roux C
Osteoporos Int; 2010 Jan; 21(1):145-55. PubMed ID: 19459025
[TBL] [Abstract][Full Text] [Related]
36. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.
Imaz I; Zegarra P; González-Enríquez J; Rubio B; Alcazar R; Amate JM
Osteoporos Int; 2010 Nov; 21(11):1943-51. PubMed ID: 19967338
[TBL] [Abstract][Full Text] [Related]
37. Impact of pharmaceutical care on knowledge, quality of life and satisfaction of postmenopausal women with osteoporosis.
Lai PS; Chua SS; Chan SP
Int J Clin Pharm; 2013 Aug; 35(4):629-37. PubMed ID: 23677816
[TBL] [Abstract][Full Text] [Related]
38. Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization.
Sunyecz JA; Mucha L; Baser O; Barr CE; Amonkar MM
Osteoporos Int; 2008 Oct; 19(10):1421-9. PubMed ID: 18351427
[TBL] [Abstract][Full Text] [Related]
39. [Monthly ibandronate attachment to Mexican and Chilean women with osteoporosis, with or without a biofeedback strategy].
García-Hernández P; Carranza-Lira S; Motta-Martínez E
Ginecol Obstet Mex; 2010 Jun; 78(6):322-8. PubMed ID: 20939245
[TBL] [Abstract][Full Text] [Related]
40. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance.
Boonen S; Vanderschueren D; Venken K; Milisen K; Delforge M; Haentjens P
J Intern Med; 2008 Oct; 264(4):315-32. PubMed ID: 18823505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
